

8/AB/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0014905802 BIOSIS NO.: 200400276559

**Compositions and methods for inhibiting cellular proliferation**

AUTHOR: Papathanassiou Adonia E (Reprint); Green Shawn J

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1282 (2): May 11, 2004 2004

MEDIUM: e-file

PATENT NUMBER: US 6734163 PATENT DATE GRANTED: May 11, 2004 20040511

PATENT CLASSIFICATION: 514-2 PATENT ASSIGNEE: EntreMed, Inc.

PATENT COUNTRY: USA

ISSN: 0098-1133 (ISSN print)

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

8/AB/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0014396660 BIOSIS NO.: 200300355379

**Quantification of tissue factor pathway inhibitor in human seminal plasma and in human follicular fluid.**

AUTHOR: Thyzel E; Siegling S; Goetting C (Reprint); Tinneberg H-R;

Brinkmann T; Kleesiek K

AUTHOR ADDRESS: Institut fuer Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitaetsklinik der Ruhr-Universitaet Bochum, Georgstrasse 11, 32545, Bad Oeynhausen, Germany  
\*\*Germany

AUTHOR E-MAIL ADDRESS: cgoetting@hdz-nrw.de

JOURNAL: Thrombosis Research 109 (5-6): p329-332 March 15, 2003 2003

MEDIUM: print

ISSN: 0049-3848

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Introduction: Tissue factor pathway inhibitor (TFPI) is a multivalent Kunitz-type serine proteinase inhibitor, which plays a central role in the extrinsic pathway of blood coagulation. It inhibits activated factor X directly and factor VIIa/tissue factor via a quaternary complex. The composition of human semen is governed by the ejaculatory mixing of sperm-rich epididymal fluid, with secretion provided by the accessory sex glands. It is composed of more than 30 proteins including coagulation and liquefaction proteins. Ovarian follicular fluid plays an important biological role in folliculogenesis and oocyte maturation, and it remains in a hypocoagulable state until

ovulation. Materials and methods: TFPI levels were measured in ovarian follicular fluid gained from the punctured follicles of superovulated women (n=70), and, for the first time, in seminal plasma of 28 healthy ejaculate donors and 23 infertile patients with oligozoospermia, asthenozoospermia, or teratozoospermia. Results: TFPI concentrations determined in liquor folliculi (median 298 ng/ml, 90% range 109-648 ng/ml) were four times higher than the levels found in human blood of healthy individuals. TFPI concentrations in seminal plasma samples of infertile men were significantly reduced (median 2.20 ng/ml, 90% range 0.28-6.02 ng/ml,  $p < 0.07$ ) in comparison to healthy donors (median 3.55 ng/ml, 90% range 0.93-7.90 ng/ml). Conclusions: The high TFPI levels measured in the ovarian follicular fluid underline the physiological importance of this inhibitor for maintaining the hypocoagulable state. The decreased TFPI concentrations in seminal plasma of infertile men support the possible correlation between the coagulation properties of ejaculated semen and male fertility.

8/AB/29 (Item 19 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

10536411 EMBASE No: 2000001157

**The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor**

Ettelaie C.; Adam J.M.; James N.J.; Oke A.O.; Harrison J.A.; Bunce T.D.; Bruckdorfer K.R.

C. Ettelaie, Dept. of Biochem./Molecular Biology, Royal Free/Univ. College Med. School, Royal Free Campus, Rowland Hill Street, London NW3 2PF United Kingdom

AUTHOR EMAIL: camille@rfhsm.ac.uk

FEBS Letters ( FEBS LETT. ) (Netherlands) 1999, 463/3 (341-344)

CODEN: FEBLA ISSN: 0014-5793

PUBLISHER ITEM IDENTIFIER: S0014579399016634

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 24

Tissue factor pathway inhibitor (TFPI) inhibits the activity of coagulation factors VIIa and Xa through Kunitz domains, thereby inhibiting the activity of tissue factor. However, it has been shown that the C-terminal of this inhibitor is essential for the maximal anticoagulant activity of TFPI. We have investigated the endogenous ability of the C-terminal of TFPI to influence coagulation. A synthetic peptide corresponding to residues 254- 265 within the C-terminal of TFPI was prepared and shown to be capable of inhibiting tissue factor pathway by preventing the activation of factor VII. Mutational analysis of the peptide revealed the identity of the key lysine residues.

8/AB/38 (Item 28 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

04994794 EMBASE No: 1992135010

**Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation**

Broze Jr. G.J.

United States

Trends in Cardiovascular Medicine ( TRENDS CARDIOVASC. MED. ) (United States) 1992, 2/2 (72-77)

CODEN: TCMDE ISSN: 1050-1738

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The recent rediscovery, isolation, and characterization of an endogenous coagulation inhibitor termed tissue factor pathway inhibitor (TFPI) has provided new insight into the regulation of in vivo coagulation. TFPI is a multivalent, Kunitz-type, protease inhibitor that directly binds and inactivates factor Xa and, in a factor-Xa-dependent fashion, produces feedback inhibition of the factor VIIa-tissue factor catalytic complex. The demonstrated in vitro properties of TFPI have led to the formulation of a revised theory of blood coagulation. In the revised model, coagulation proceeds through a single pathway rather than the alternative and redundant 'extrinsic' and 'intrinsic' pathways that had previously been postulated.

**8/AB/39 (Item 1 from file: 399)**

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

**139079186 CA: 139(6)79186k PATENT**

**Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)**

INVENTOR(AUTHOR): Creasey, Alba A.

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200355442 A2 DATE: 20030710

APPLICATION: WO 2002US32625 (20021015) \*US PV328806 (20011015)

PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

**8/AB/40 (Item 2 from file: 399)**

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

**138314551 CA: 138(21)314551r PATENT**

**Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI) or TFPI analogs**

INVENTOR(AUTHOR): Creasey, Abba A.

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200332904 A2 DATE: 20030424

APPLICATION: WO 2002US32624 (20021015) \*US PV328806 (20011015)

PAGES: 39 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;

LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS  
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;  
ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI;  
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/AB/41 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

135352804 CA: 135(25)352804w PATENT

Pharmaceutical composition comprising a factor VIIa and a TFPI inhibitor  
combination as coagulants

INVENTOR(AUTHOR): Kjalke, Marianne

LOCATION: Den.

ASSIGNEE: Novo Nordisk A/S

PATENT: PCT International ; WO 200185199 A1 DATE: 20011115

APPLICATION: WO 2001DK324 (20010510) \*DK 2000771 (20000510) \*DK 2000778  
(20000510) \*US PV206212 (20000522) \*US PV206194 (20000522) \*DK 2000871  
(20000606) \*US PV212857 (20000620)

PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/36A;  
A61P-007/04B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE;  
GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;  
LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG;  
SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY;  
KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL  
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;  
MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD;  
TG  
?

Set	Items	Description
S1	2818	TFPI
S2	1775	TISSUE FACTOR PATHWAY INHIBITOR
S3	3611	S1 OR S2
S4	16111	STABLIZED OR LYOPHILIZED
S5	1	S3 AND S4
S6	1300906	COMPOSITION OR FORMULATION
S7	54	S3 AND S6
S8	41	RD S7 (unique items)
?		